Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3668 - Patient Demographics and Management Landscape of Metastatic Colorectal Cancer in the Third Line Setting: real-world data in an Australian Population

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Sandy Tun Min

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

S. Tun Min1, A. Roohullah1, A. Tognela1, A. Jalali2, M. Lee3, R. Wong4, J. Shapiro5, M. Burge6, D. Yip7, L. Nott8, A. Zimet9, B. Lee10, A. Dean11, S. Steel12, H. Wong2, P. Gibbs2, S.H. Lim1

Author affiliations

  • 1 Medical Oncology, Macarthur Cancer Therapy Centre, 2560 - Campbelltown/AU
  • 2 Personalised Oncology Division, Walter & Eliza Hall Institute of Medical Research, Parkville/AU
  • 3 Medical Oncology, Footscray Hospital, Western Health, Footscray/AU
  • 4 Dept Of Medical Oncology, Eastern Health, 3128 - Box Hill/AU
  • 5 Medical Oncology, Cabrini Health, Malvern/AU
  • 6 Dept Of Medical Oncology, Royal Brisbane & Women's Hospital, Brisbane/AU
  • 7 Medical Oncology, Canberra and Calvary Hospitals, 2605 - Garran/AU
  • 8 Medical Oncology, Royal Hobart Hospital, Hobart/AU
  • 9 Medical Oncology, Epworth HealthCare, Richmond/AU
  • 10 Medical Oncology, The Northern Hospital, Epping/AU
  • 11 Dept Of Medical Oncology, St John of God Subiaco Hospital, Perth/AU
  • 12 Medical Oncology, Peninsula Private Hospital, Frankston/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3668

Background

Colorectal cancer is the third most common cancer and second leading cause of cancer mortality in Australia. In patients with metastatic disease who have progressed after two lines of therapies, survival is 4-6 months with best supportive care, and 6-8 months with newer agents. This retrospective analysis aims to explore real-world treatment landscape of metastatic colorectal cancer in the third-line setting.

Methods

We analysed the TRACC (Treatment of Recurrent and Advanced Colorectal Cancer) registry database from 2009 onwards. Patients treated with palliative intent who have progressed after two lines of therapies were included. One treatment line is defined as any combination of systemic therapy given until progression. Patient demographics, third line choices and survival outcomes were examined.

Results

A total of 2831 patients had metastatic colorectal cancer, and of these, 23% (642 patients) met study criteria. 48% (306 patients) of study population proceeded to receive third line therapy. A large proportion of patients had received doublet chemotherapy in both first and second lines. Median age was 62 years and ECOG at the start of third line was 1-2 (75%). A fluoropyrimidine-based doublet with oxaliplatin or irinotecan was the most common treatment choice in 42%. Other treatments included mono-chemotherapy +/- biological agent (23%), EGFR inhibitor alone (22%), EGFR inhibitor with doublet chemotherapy (6%), trifluridine/tipiracil (4%), regorafenib (2%), immunotherapy (<1%), clinical trials (1%), others (<1%). Median duration on third-line treatment was 2.4 months (0.07 – 40). Median overall survival (OS) was 8.7 months (0.4 – 58).

Conclusions

In a real-world Australian population, 11% of all patients diagnosed with metastatic disease received third line treatment, with commonest regimens being doublet chemotherapy. This treatment landscape may change with the approval of new drugs. Overall survival in these patients is comparable to third line trials on these agents. Analyses are underway to further characterise the breakdown of treatment regimens in all three lines in these patients, and assess survival with rechallenge regimens.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.